Global Anti-angiogenic Ophthalmic Agent Supply, Demand and Key Producers, 2023-2029
The global Anti-angiogenic Ophthalmic Agent market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue.
This report studies the global Anti-angiogenic Ophthalmic Agent production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Anti-angiogenic Ophthalmic Agent, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Anti-angiogenic Ophthalmic Agent that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Anti-angiogenic Ophthalmic Agent total production and demand, 2018-2029, (K Units)
Global Anti-angiogenic Ophthalmic Agent total production value, 2018-2029, (USD Million)
Global Anti-angiogenic Ophthalmic Agent production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Anti-angiogenic Ophthalmic Agent consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Anti-angiogenic Ophthalmic Agent domestic production, consumption, key domestic manufacturers and share
Global Anti-angiogenic Ophthalmic Agent production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Anti-angiogenic Ophthalmic Agent production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Anti-angiogenic Ophthalmic Agent production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Anti-angiogenic Ophthalmic Agent market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG and Santen Pharmaceutical Co., Ltd., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Anti-angiogenic Ophthalmic Agent market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Anti-angiogenic Ophthalmic Agent Market, By Region:
1. How big is the global Anti-angiogenic Ophthalmic Agent market?
2. What is the demand of the global Anti-angiogenic Ophthalmic Agent market?
3. What is the year over year growth of the global Anti-angiogenic Ophthalmic Agent market?
4. What is the production and production value of the global Anti-angiogenic Ophthalmic Agent market?
5. Who are the key producers in the global Anti-angiogenic Ophthalmic Agent market?
6. What are the growth factors driving the market demand?
Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue.
This report studies the global Anti-angiogenic Ophthalmic Agent production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Anti-angiogenic Ophthalmic Agent, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Anti-angiogenic Ophthalmic Agent that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Anti-angiogenic Ophthalmic Agent total production and demand, 2018-2029, (K Units)
Global Anti-angiogenic Ophthalmic Agent total production value, 2018-2029, (USD Million)
Global Anti-angiogenic Ophthalmic Agent production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Anti-angiogenic Ophthalmic Agent consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Anti-angiogenic Ophthalmic Agent domestic production, consumption, key domestic manufacturers and share
Global Anti-angiogenic Ophthalmic Agent production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Anti-angiogenic Ophthalmic Agent production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Anti-angiogenic Ophthalmic Agent production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Anti-angiogenic Ophthalmic Agent market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG and Santen Pharmaceutical Co., Ltd., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Anti-angiogenic Ophthalmic Agent market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Anti-angiogenic Ophthalmic Agent Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Myopic Choroidal Neovascularization
- Macular Edema
- Diabetic Retinopathy
- Macular Degeneration
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
- Gilead Sciences, Inc.
- Eyetech Inc.
- Becton, Dickinson and Company
- Regeneron Pharmaceuticals, Inc.
- Genentech, Inc.
- Novartis AG
- Allergan plc
- Bayer AG
- Santen Pharmaceutical Co., Ltd.
- Shanghai Pharmaceuticals
- Johnson & Johnson
- Pfizer
- Sun Pharma
- Otsuka Pharmaceutical Co. Ltd
- Daiichi Sankyo
- ERC Labs
- Medicom Health care
- Implant ophthalmic products GmbH
- The Geuder Group, MORCHER GmbH
- Novamedika
1. How big is the global Anti-angiogenic Ophthalmic Agent market?
2. What is the demand of the global Anti-angiogenic Ophthalmic Agent market?
3. What is the year over year growth of the global Anti-angiogenic Ophthalmic Agent market?
4. What is the production and production value of the global Anti-angiogenic Ophthalmic Agent market?
5. Who are the key producers in the global Anti-angiogenic Ophthalmic Agent market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Anti-angiogenic Ophthalmic Agent Introduction
1.2 World Anti-angiogenic Ophthalmic Agent Supply & Forecast
1.2.1 World Anti-angiogenic Ophthalmic Agent Production Value (2018 & 2022 & 2029)
1.2.2 World Anti-angiogenic Ophthalmic Agent Production (2018-2029)
1.2.3 World Anti-angiogenic Ophthalmic Agent Pricing Trends (2018-2029)
1.3 World Anti-angiogenic Ophthalmic Agent Production by Region (Based on Production Site)
1.3.1 World Anti-angiogenic Ophthalmic Agent Production Value by Region (2018-2029)
1.3.2 World Anti-angiogenic Ophthalmic Agent Production by Region (2018-2029)
1.3.3 World Anti-angiogenic Ophthalmic Agent Average Price by Region (2018-2029)
1.3.4 North America Anti-angiogenic Ophthalmic Agent Production (2018-2029)
1.3.5 Europe Anti-angiogenic Ophthalmic Agent Production (2018-2029)
1.3.6 China Anti-angiogenic Ophthalmic Agent Production (2018-2029)
1.3.7 Japan Anti-angiogenic Ophthalmic Agent Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Anti-angiogenic Ophthalmic Agent Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Anti-angiogenic Ophthalmic Agent Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Anti-angiogenic Ophthalmic Agent Demand (2018-2029)
2.2 World Anti-angiogenic Ophthalmic Agent Consumption by Region
2.2.1 World Anti-angiogenic Ophthalmic Agent Consumption by Region (2018-2023)
2.2.2 World Anti-angiogenic Ophthalmic Agent Consumption Forecast by Region (2024-2029)
2.3 United States Anti-angiogenic Ophthalmic Agent Consumption (2018-2029)
2.4 China Anti-angiogenic Ophthalmic Agent Consumption (2018-2029)
2.5 Europe Anti-angiogenic Ophthalmic Agent Consumption (2018-2029)
2.6 Japan Anti-angiogenic Ophthalmic Agent Consumption (2018-2029)
2.7 South Korea Anti-angiogenic Ophthalmic Agent Consumption (2018-2029)
2.8 ASEAN Anti-angiogenic Ophthalmic Agent Consumption (2018-2029)
2.9 India Anti-angiogenic Ophthalmic Agent Consumption (2018-2029)
3 WORLD ANTI-ANGIOGENIC OPHTHALMIC AGENT MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Anti-angiogenic Ophthalmic Agent Production Value by Manufacturer (2018-2023)
3.2 World Anti-angiogenic Ophthalmic Agent Production by Manufacturer (2018-2023)
3.3 World Anti-angiogenic Ophthalmic Agent Average Price by Manufacturer (2018-2023)
3.4 Anti-angiogenic Ophthalmic Agent Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Anti-angiogenic Ophthalmic Agent Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Anti-angiogenic Ophthalmic Agent in 2022
3.5.3 Global Concentration Ratios (CR8) for Anti-angiogenic Ophthalmic Agent in 2022
3.6 Anti-angiogenic Ophthalmic Agent Market: Overall Company Footprint Analysis
3.6.1 Anti-angiogenic Ophthalmic Agent Market: Region Footprint
3.6.2 Anti-angiogenic Ophthalmic Agent Market: Company Product Type Footprint
3.6.3 Anti-angiogenic Ophthalmic Agent Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Anti-angiogenic Ophthalmic Agent Production Value Comparison
4.1.1 United States VS China: Anti-angiogenic Ophthalmic Agent Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Anti-angiogenic Ophthalmic Agent Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Anti-angiogenic Ophthalmic Agent Production Comparison
4.2.1 United States VS China: Anti-angiogenic Ophthalmic Agent Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Anti-angiogenic Ophthalmic Agent Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Anti-angiogenic Ophthalmic Agent Consumption Comparison
4.3.1 United States VS China: Anti-angiogenic Ophthalmic Agent Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Anti-angiogenic Ophthalmic Agent Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Anti-angiogenic Ophthalmic Agent Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Anti-angiogenic Ophthalmic Agent Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value (2018-2023)
4.4.3 United States Based Manufacturers Anti-angiogenic Ophthalmic Agent Production (2018-2023)
4.5 China Based Anti-angiogenic Ophthalmic Agent Manufacturers and Market Share
4.5.1 China Based Anti-angiogenic Ophthalmic Agent Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value (2018-2023)
4.5.3 China Based Manufacturers Anti-angiogenic Ophthalmic Agent Production (2018-2023)
4.6 Rest of World Based Anti-angiogenic Ophthalmic Agent Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Anti-angiogenic Ophthalmic Agent Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Anti-angiogenic Ophthalmic Agent Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Anti-angiogenic Ophthalmic Agent Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Myopic Choroidal Neovascularization
5.2.2 Macular Edema
5.2.3 Diabetic Retinopathy
5.2.4 Macular Degeneration
5.3 Market Segment by Type
5.3.1 World Anti-angiogenic Ophthalmic Agent Production by Type (2018-2029)
5.3.2 World Anti-angiogenic Ophthalmic Agent Production Value by Type (2018-2029)
5.3.3 World Anti-angiogenic Ophthalmic Agent Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Anti-angiogenic Ophthalmic Agent Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Retail Pharmacies
6.2.2 Online Pharmacies
6.2.3 Hospital Pharmacies
6.3 Market Segment by Application
6.3.1 World Anti-angiogenic Ophthalmic Agent Production by Application (2018-2029)
6.3.2 World Anti-angiogenic Ophthalmic Agent Production Value by Application (2018-2029)
6.3.3 World Anti-angiogenic Ophthalmic Agent Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Gilead Sciences, Inc.
7.1.1 Gilead Sciences, Inc. Details
7.1.2 Gilead Sciences, Inc. Major Business
7.1.3 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
7.1.4 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Gilead Sciences, Inc. Recent Developments/Updates
7.1.6 Gilead Sciences, Inc. Competitive Strengths & Weaknesses
7.2 Eyetech Inc.
7.2.1 Eyetech Inc. Details
7.2.2 Eyetech Inc. Major Business
7.2.3 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product and Services
7.2.4 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Eyetech Inc. Recent Developments/Updates
7.2.6 Eyetech Inc. Competitive Strengths & Weaknesses
7.3 Becton, Dickinson and Company
7.3.1 Becton, Dickinson and Company Details
7.3.2 Becton, Dickinson and Company Major Business
7.3.3 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product and Services
7.3.4 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Becton, Dickinson and Company Recent Developments/Updates
7.3.6 Becton, Dickinson and Company Competitive Strengths & Weaknesses
7.4 Regeneron Pharmaceuticals, Inc.
7.4.1 Regeneron Pharmaceuticals, Inc. Details
7.4.2 Regeneron Pharmaceuticals, Inc. Major Business
7.4.3 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
7.4.4 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
7.4.6 Regeneron Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
7.5 Genentech, Inc.
7.5.1 Genentech, Inc. Details
7.5.2 Genentech, Inc. Major Business
7.5.3 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
7.5.4 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Genentech, Inc. Recent Developments/Updates
7.5.6 Genentech, Inc. Competitive Strengths & Weaknesses
7.6 Novartis AG
7.6.1 Novartis AG Details
7.6.2 Novartis AG Major Business
7.6.3 Novartis AG Anti-angiogenic Ophthalmic Agent Product and Services
7.6.4 Novartis AG Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Novartis AG Recent Developments/Updates
7.6.6 Novartis AG Competitive Strengths & Weaknesses
7.7 Allergan plc
7.7.1 Allergan plc Details
7.7.2 Allergan plc Major Business
7.7.3 Allergan plc Anti-angiogenic Ophthalmic Agent Product and Services
7.7.4 Allergan plc Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Allergan plc Recent Developments/Updates
7.7.6 Allergan plc Competitive Strengths & Weaknesses
7.8 Bayer AG
7.8.1 Bayer AG Details
7.8.2 Bayer AG Major Business
7.8.3 Bayer AG Anti-angiogenic Ophthalmic Agent Product and Services
7.8.4 Bayer AG Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Bayer AG Recent Developments/Updates
7.8.6 Bayer AG Competitive Strengths & Weaknesses
7.9 Santen Pharmaceutical Co., Ltd.
7.9.1 Santen Pharmaceutical Co., Ltd. Details
7.9.2 Santen Pharmaceutical Co., Ltd. Major Business
7.9.3 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product and Services
7.9.4 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 Santen Pharmaceutical Co., Ltd. Recent Developments/Updates
7.9.6 Santen Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
7.10 Shanghai Pharmaceuticals
7.10.1 Shanghai Pharmaceuticals Details
7.10.2 Shanghai Pharmaceuticals Major Business
7.10.3 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product and Services
7.10.4 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Shanghai Pharmaceuticals Recent Developments/Updates
7.10.6 Shanghai Pharmaceuticals Competitive Strengths & Weaknesses
7.11 Johnson & Johnson
7.11.1 Johnson & Johnson Details
7.11.2 Johnson & Johnson Major Business
7.11.3 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product and Services
7.11.4 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.11.5 Johnson & Johnson Recent Developments/Updates
7.11.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.12 Pfizer
7.12.1 Pfizer Details
7.12.2 Pfizer Major Business
7.12.3 Pfizer Anti-angiogenic Ophthalmic Agent Product and Services
7.12.4 Pfizer Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.12.5 Pfizer Recent Developments/Updates
7.12.6 Pfizer Competitive Strengths & Weaknesses
7.13 Sun Pharma
7.13.1 Sun Pharma Details
7.13.2 Sun Pharma Major Business
7.13.3 Sun Pharma Anti-angiogenic Ophthalmic Agent Product and Services
7.13.4 Sun Pharma Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.13.5 Sun Pharma Recent Developments/Updates
7.13.6 Sun Pharma Competitive Strengths & Weaknesses
7.14 Otsuka Pharmaceutical Co. Ltd
7.14.1 Otsuka Pharmaceutical Co. Ltd Details
7.14.2 Otsuka Pharmaceutical Co. Ltd Major Business
7.14.3 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product and Services
7.14.4 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.14.5 Otsuka Pharmaceutical Co. Ltd Recent Developments/Updates
7.14.6 Otsuka Pharmaceutical Co. Ltd Competitive Strengths & Weaknesses
7.15 Daiichi Sankyo
7.15.1 Daiichi Sankyo Details
7.15.2 Daiichi Sankyo Major Business
7.15.3 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product and Services
7.15.4 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.15.5 Daiichi Sankyo Recent Developments/Updates
7.15.6 Daiichi Sankyo Competitive Strengths & Weaknesses
7.16 ERC Labs
7.16.1 ERC Labs Details
7.16.2 ERC Labs Major Business
7.16.3 ERC Labs Anti-angiogenic Ophthalmic Agent Product and Services
7.16.4 ERC Labs Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.16.5 ERC Labs Recent Developments/Updates
7.16.6 ERC Labs Competitive Strengths & Weaknesses
7.17 Medicom Health care
7.17.1 Medicom Health care Details
7.17.2 Medicom Health care Major Business
7.17.3 Medicom Health care Anti-angiogenic Ophthalmic Agent Product and Services
7.17.4 Medicom Health care Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.17.5 Medicom Health care Recent Developments/Updates
7.17.6 Medicom Health care Competitive Strengths & Weaknesses
7.18 Implant ophthalmic products GmbH
7.18.1 Implant ophthalmic products GmbH Details
7.18.2 Implant ophthalmic products GmbH Major Business
7.18.3 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product and Services
7.18.4 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.18.5 Implant ophthalmic products GmbH Recent Developments/Updates
7.18.6 Implant ophthalmic products GmbH Competitive Strengths & Weaknesses
7.19 The Geuder Group, MORCHER GmbH
7.19.1 The Geuder Group, MORCHER GmbH Details
7.19.2 The Geuder Group, MORCHER GmbH Major Business
7.19.3 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product and Services
7.19.4 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.19.5 The Geuder Group, MORCHER GmbH Recent Developments/Updates
7.19.6 The Geuder Group, MORCHER GmbH Competitive Strengths & Weaknesses
7.20 Novamedika
7.20.1 Novamedika Details
7.20.2 Novamedika Major Business
7.20.3 Novamedika Anti-angiogenic Ophthalmic Agent Product and Services
7.20.4 Novamedika Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.20.5 Novamedika Recent Developments/Updates
7.20.6 Novamedika Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Anti-angiogenic Ophthalmic Agent Industry Chain
8.2 Anti-angiogenic Ophthalmic Agent Upstream Analysis
8.2.1 Anti-angiogenic Ophthalmic Agent Core Raw Materials
8.2.2 Main Manufacturers of Anti-angiogenic Ophthalmic Agent Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Anti-angiogenic Ophthalmic Agent Production Mode
8.6 Anti-angiogenic Ophthalmic Agent Procurement Model
8.7 Anti-angiogenic Ophthalmic Agent Industry Sales Model and Sales Channels
8.7.1 Anti-angiogenic Ophthalmic Agent Sales Model
8.7.2 Anti-angiogenic Ophthalmic Agent Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Anti-angiogenic Ophthalmic Agent Introduction
1.2 World Anti-angiogenic Ophthalmic Agent Supply & Forecast
1.2.1 World Anti-angiogenic Ophthalmic Agent Production Value (2018 & 2022 & 2029)
1.2.2 World Anti-angiogenic Ophthalmic Agent Production (2018-2029)
1.2.3 World Anti-angiogenic Ophthalmic Agent Pricing Trends (2018-2029)
1.3 World Anti-angiogenic Ophthalmic Agent Production by Region (Based on Production Site)
1.3.1 World Anti-angiogenic Ophthalmic Agent Production Value by Region (2018-2029)
1.3.2 World Anti-angiogenic Ophthalmic Agent Production by Region (2018-2029)
1.3.3 World Anti-angiogenic Ophthalmic Agent Average Price by Region (2018-2029)
1.3.4 North America Anti-angiogenic Ophthalmic Agent Production (2018-2029)
1.3.5 Europe Anti-angiogenic Ophthalmic Agent Production (2018-2029)
1.3.6 China Anti-angiogenic Ophthalmic Agent Production (2018-2029)
1.3.7 Japan Anti-angiogenic Ophthalmic Agent Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Anti-angiogenic Ophthalmic Agent Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Anti-angiogenic Ophthalmic Agent Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Anti-angiogenic Ophthalmic Agent Demand (2018-2029)
2.2 World Anti-angiogenic Ophthalmic Agent Consumption by Region
2.2.1 World Anti-angiogenic Ophthalmic Agent Consumption by Region (2018-2023)
2.2.2 World Anti-angiogenic Ophthalmic Agent Consumption Forecast by Region (2024-2029)
2.3 United States Anti-angiogenic Ophthalmic Agent Consumption (2018-2029)
2.4 China Anti-angiogenic Ophthalmic Agent Consumption (2018-2029)
2.5 Europe Anti-angiogenic Ophthalmic Agent Consumption (2018-2029)
2.6 Japan Anti-angiogenic Ophthalmic Agent Consumption (2018-2029)
2.7 South Korea Anti-angiogenic Ophthalmic Agent Consumption (2018-2029)
2.8 ASEAN Anti-angiogenic Ophthalmic Agent Consumption (2018-2029)
2.9 India Anti-angiogenic Ophthalmic Agent Consumption (2018-2029)
3 WORLD ANTI-ANGIOGENIC OPHTHALMIC AGENT MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Anti-angiogenic Ophthalmic Agent Production Value by Manufacturer (2018-2023)
3.2 World Anti-angiogenic Ophthalmic Agent Production by Manufacturer (2018-2023)
3.3 World Anti-angiogenic Ophthalmic Agent Average Price by Manufacturer (2018-2023)
3.4 Anti-angiogenic Ophthalmic Agent Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Anti-angiogenic Ophthalmic Agent Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Anti-angiogenic Ophthalmic Agent in 2022
3.5.3 Global Concentration Ratios (CR8) for Anti-angiogenic Ophthalmic Agent in 2022
3.6 Anti-angiogenic Ophthalmic Agent Market: Overall Company Footprint Analysis
3.6.1 Anti-angiogenic Ophthalmic Agent Market: Region Footprint
3.6.2 Anti-angiogenic Ophthalmic Agent Market: Company Product Type Footprint
3.6.3 Anti-angiogenic Ophthalmic Agent Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Anti-angiogenic Ophthalmic Agent Production Value Comparison
4.1.1 United States VS China: Anti-angiogenic Ophthalmic Agent Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Anti-angiogenic Ophthalmic Agent Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Anti-angiogenic Ophthalmic Agent Production Comparison
4.2.1 United States VS China: Anti-angiogenic Ophthalmic Agent Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Anti-angiogenic Ophthalmic Agent Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Anti-angiogenic Ophthalmic Agent Consumption Comparison
4.3.1 United States VS China: Anti-angiogenic Ophthalmic Agent Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Anti-angiogenic Ophthalmic Agent Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Anti-angiogenic Ophthalmic Agent Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Anti-angiogenic Ophthalmic Agent Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value (2018-2023)
4.4.3 United States Based Manufacturers Anti-angiogenic Ophthalmic Agent Production (2018-2023)
4.5 China Based Anti-angiogenic Ophthalmic Agent Manufacturers and Market Share
4.5.1 China Based Anti-angiogenic Ophthalmic Agent Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value (2018-2023)
4.5.3 China Based Manufacturers Anti-angiogenic Ophthalmic Agent Production (2018-2023)
4.6 Rest of World Based Anti-angiogenic Ophthalmic Agent Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Anti-angiogenic Ophthalmic Agent Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Anti-angiogenic Ophthalmic Agent Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Anti-angiogenic Ophthalmic Agent Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Myopic Choroidal Neovascularization
5.2.2 Macular Edema
5.2.3 Diabetic Retinopathy
5.2.4 Macular Degeneration
5.3 Market Segment by Type
5.3.1 World Anti-angiogenic Ophthalmic Agent Production by Type (2018-2029)
5.3.2 World Anti-angiogenic Ophthalmic Agent Production Value by Type (2018-2029)
5.3.3 World Anti-angiogenic Ophthalmic Agent Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Anti-angiogenic Ophthalmic Agent Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Retail Pharmacies
6.2.2 Online Pharmacies
6.2.3 Hospital Pharmacies
6.3 Market Segment by Application
6.3.1 World Anti-angiogenic Ophthalmic Agent Production by Application (2018-2029)
6.3.2 World Anti-angiogenic Ophthalmic Agent Production Value by Application (2018-2029)
6.3.3 World Anti-angiogenic Ophthalmic Agent Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Gilead Sciences, Inc.
7.1.1 Gilead Sciences, Inc. Details
7.1.2 Gilead Sciences, Inc. Major Business
7.1.3 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
7.1.4 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Gilead Sciences, Inc. Recent Developments/Updates
7.1.6 Gilead Sciences, Inc. Competitive Strengths & Weaknesses
7.2 Eyetech Inc.
7.2.1 Eyetech Inc. Details
7.2.2 Eyetech Inc. Major Business
7.2.3 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product and Services
7.2.4 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Eyetech Inc. Recent Developments/Updates
7.2.6 Eyetech Inc. Competitive Strengths & Weaknesses
7.3 Becton, Dickinson and Company
7.3.1 Becton, Dickinson and Company Details
7.3.2 Becton, Dickinson and Company Major Business
7.3.3 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product and Services
7.3.4 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Becton, Dickinson and Company Recent Developments/Updates
7.3.6 Becton, Dickinson and Company Competitive Strengths & Weaknesses
7.4 Regeneron Pharmaceuticals, Inc.
7.4.1 Regeneron Pharmaceuticals, Inc. Details
7.4.2 Regeneron Pharmaceuticals, Inc. Major Business
7.4.3 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
7.4.4 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
7.4.6 Regeneron Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
7.5 Genentech, Inc.
7.5.1 Genentech, Inc. Details
7.5.2 Genentech, Inc. Major Business
7.5.3 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
7.5.4 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Genentech, Inc. Recent Developments/Updates
7.5.6 Genentech, Inc. Competitive Strengths & Weaknesses
7.6 Novartis AG
7.6.1 Novartis AG Details
7.6.2 Novartis AG Major Business
7.6.3 Novartis AG Anti-angiogenic Ophthalmic Agent Product and Services
7.6.4 Novartis AG Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Novartis AG Recent Developments/Updates
7.6.6 Novartis AG Competitive Strengths & Weaknesses
7.7 Allergan plc
7.7.1 Allergan plc Details
7.7.2 Allergan plc Major Business
7.7.3 Allergan plc Anti-angiogenic Ophthalmic Agent Product and Services
7.7.4 Allergan plc Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Allergan plc Recent Developments/Updates
7.7.6 Allergan plc Competitive Strengths & Weaknesses
7.8 Bayer AG
7.8.1 Bayer AG Details
7.8.2 Bayer AG Major Business
7.8.3 Bayer AG Anti-angiogenic Ophthalmic Agent Product and Services
7.8.4 Bayer AG Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Bayer AG Recent Developments/Updates
7.8.6 Bayer AG Competitive Strengths & Weaknesses
7.9 Santen Pharmaceutical Co., Ltd.
7.9.1 Santen Pharmaceutical Co., Ltd. Details
7.9.2 Santen Pharmaceutical Co., Ltd. Major Business
7.9.3 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product and Services
7.9.4 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 Santen Pharmaceutical Co., Ltd. Recent Developments/Updates
7.9.6 Santen Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
7.10 Shanghai Pharmaceuticals
7.10.1 Shanghai Pharmaceuticals Details
7.10.2 Shanghai Pharmaceuticals Major Business
7.10.3 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product and Services
7.10.4 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Shanghai Pharmaceuticals Recent Developments/Updates
7.10.6 Shanghai Pharmaceuticals Competitive Strengths & Weaknesses
7.11 Johnson & Johnson
7.11.1 Johnson & Johnson Details
7.11.2 Johnson & Johnson Major Business
7.11.3 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product and Services
7.11.4 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.11.5 Johnson & Johnson Recent Developments/Updates
7.11.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.12 Pfizer
7.12.1 Pfizer Details
7.12.2 Pfizer Major Business
7.12.3 Pfizer Anti-angiogenic Ophthalmic Agent Product and Services
7.12.4 Pfizer Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.12.5 Pfizer Recent Developments/Updates
7.12.6 Pfizer Competitive Strengths & Weaknesses
7.13 Sun Pharma
7.13.1 Sun Pharma Details
7.13.2 Sun Pharma Major Business
7.13.3 Sun Pharma Anti-angiogenic Ophthalmic Agent Product and Services
7.13.4 Sun Pharma Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.13.5 Sun Pharma Recent Developments/Updates
7.13.6 Sun Pharma Competitive Strengths & Weaknesses
7.14 Otsuka Pharmaceutical Co. Ltd
7.14.1 Otsuka Pharmaceutical Co. Ltd Details
7.14.2 Otsuka Pharmaceutical Co. Ltd Major Business
7.14.3 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product and Services
7.14.4 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.14.5 Otsuka Pharmaceutical Co. Ltd Recent Developments/Updates
7.14.6 Otsuka Pharmaceutical Co. Ltd Competitive Strengths & Weaknesses
7.15 Daiichi Sankyo
7.15.1 Daiichi Sankyo Details
7.15.2 Daiichi Sankyo Major Business
7.15.3 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product and Services
7.15.4 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.15.5 Daiichi Sankyo Recent Developments/Updates
7.15.6 Daiichi Sankyo Competitive Strengths & Weaknesses
7.16 ERC Labs
7.16.1 ERC Labs Details
7.16.2 ERC Labs Major Business
7.16.3 ERC Labs Anti-angiogenic Ophthalmic Agent Product and Services
7.16.4 ERC Labs Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.16.5 ERC Labs Recent Developments/Updates
7.16.6 ERC Labs Competitive Strengths & Weaknesses
7.17 Medicom Health care
7.17.1 Medicom Health care Details
7.17.2 Medicom Health care Major Business
7.17.3 Medicom Health care Anti-angiogenic Ophthalmic Agent Product and Services
7.17.4 Medicom Health care Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.17.5 Medicom Health care Recent Developments/Updates
7.17.6 Medicom Health care Competitive Strengths & Weaknesses
7.18 Implant ophthalmic products GmbH
7.18.1 Implant ophthalmic products GmbH Details
7.18.2 Implant ophthalmic products GmbH Major Business
7.18.3 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product and Services
7.18.4 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.18.5 Implant ophthalmic products GmbH Recent Developments/Updates
7.18.6 Implant ophthalmic products GmbH Competitive Strengths & Weaknesses
7.19 The Geuder Group, MORCHER GmbH
7.19.1 The Geuder Group, MORCHER GmbH Details
7.19.2 The Geuder Group, MORCHER GmbH Major Business
7.19.3 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product and Services
7.19.4 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.19.5 The Geuder Group, MORCHER GmbH Recent Developments/Updates
7.19.6 The Geuder Group, MORCHER GmbH Competitive Strengths & Weaknesses
7.20 Novamedika
7.20.1 Novamedika Details
7.20.2 Novamedika Major Business
7.20.3 Novamedika Anti-angiogenic Ophthalmic Agent Product and Services
7.20.4 Novamedika Anti-angiogenic Ophthalmic Agent Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.20.5 Novamedika Recent Developments/Updates
7.20.6 Novamedika Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Anti-angiogenic Ophthalmic Agent Industry Chain
8.2 Anti-angiogenic Ophthalmic Agent Upstream Analysis
8.2.1 Anti-angiogenic Ophthalmic Agent Core Raw Materials
8.2.2 Main Manufacturers of Anti-angiogenic Ophthalmic Agent Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Anti-angiogenic Ophthalmic Agent Production Mode
8.6 Anti-angiogenic Ophthalmic Agent Procurement Model
8.7 Anti-angiogenic Ophthalmic Agent Industry Sales Model and Sales Channels
8.7.1 Anti-angiogenic Ophthalmic Agent Sales Model
8.7.2 Anti-angiogenic Ophthalmic Agent Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Anti-angiogenic Ophthalmic Agent Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Anti-angiogenic Ophthalmic Agent Production Value by Region (2018-2023) & (USD Million)
Table 3. World Anti-angiogenic Ophthalmic Agent Production Value by Region (2024-2029) & (USD Million)
Table 4. World Anti-angiogenic Ophthalmic Agent Production Value Market Share by Region (2018-2023)
Table 5. World Anti-angiogenic Ophthalmic Agent Production Value Market Share by Region (2024-2029)
Table 6. World Anti-angiogenic Ophthalmic Agent Production by Region (2018-2023) & (K Units)
Table 7. World Anti-angiogenic Ophthalmic Agent Production by Region (2024-2029) & (K Units)
Table 8. World Anti-angiogenic Ophthalmic Agent Production Market Share by Region (2018-2023)
Table 9. World Anti-angiogenic Ophthalmic Agent Production Market Share by Region (2024-2029)
Table 10. World Anti-angiogenic Ophthalmic Agent Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Anti-angiogenic Ophthalmic Agent Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Anti-angiogenic Ophthalmic Agent Major Market Trends
Table 13. World Anti-angiogenic Ophthalmic Agent Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Anti-angiogenic Ophthalmic Agent Consumption by Region (2018-2023) & (K Units)
Table 15. World Anti-angiogenic Ophthalmic Agent Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Anti-angiogenic Ophthalmic Agent Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Anti-angiogenic Ophthalmic Agent Producers in 2022
Table 18. World Anti-angiogenic Ophthalmic Agent Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Anti-angiogenic Ophthalmic Agent Producers in 2022
Table 20. World Anti-angiogenic Ophthalmic Agent Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Anti-angiogenic Ophthalmic Agent Company Evaluation Quadrant
Table 22. World Anti-angiogenic Ophthalmic Agent Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Anti-angiogenic Ophthalmic Agent Production Site of Key Manufacturer
Table 24. Anti-angiogenic Ophthalmic Agent Market: Company Product Type Footprint
Table 25. Anti-angiogenic Ophthalmic Agent Market: Company Product Application Footprint
Table 26. Anti-angiogenic Ophthalmic Agent Competitive Factors
Table 27. Anti-angiogenic Ophthalmic Agent New Entrant and Capacity Expansion Plans
Table 28. Anti-angiogenic Ophthalmic Agent Mergers & Acquisitions Activity
Table 29. United States VS China Anti-angiogenic Ophthalmic Agent Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Anti-angiogenic Ophthalmic Agent Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Anti-angiogenic Ophthalmic Agent Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Anti-angiogenic Ophthalmic Agent Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Anti-angiogenic Ophthalmic Agent Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Market Share (2018-2023)
Table 37. China Based Anti-angiogenic Ophthalmic Agent Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Anti-angiogenic Ophthalmic Agent Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Market Share (2018-2023)
Table 42. Rest of World Based Anti-angiogenic Ophthalmic Agent Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Anti-angiogenic Ophthalmic Agent Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Market Share (2018-2023)
Table 47. World Anti-angiogenic Ophthalmic Agent Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Anti-angiogenic Ophthalmic Agent Production by Type (2018-2023) & (K Units)
Table 49. World Anti-angiogenic Ophthalmic Agent Production by Type (2024-2029) & (K Units)
Table 50. World Anti-angiogenic Ophthalmic Agent Production Value by Type (2018-2023) & (USD Million)
Table 51. World Anti-angiogenic Ophthalmic Agent Production Value by Type (2024-2029) & (USD Million)
Table 52. World Anti-angiogenic Ophthalmic Agent Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Anti-angiogenic Ophthalmic Agent Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Anti-angiogenic Ophthalmic Agent Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Anti-angiogenic Ophthalmic Agent Production by Application (2018-2023) & (K Units)
Table 56. World Anti-angiogenic Ophthalmic Agent Production by Application (2024-2029) & (K Units)
Table 57. World Anti-angiogenic Ophthalmic Agent Production Value by Application (2018-2023) & (USD Million)
Table 58. World Anti-angiogenic Ophthalmic Agent Production Value by Application (2024-2029) & (USD Million)
Table 59. World Anti-angiogenic Ophthalmic Agent Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Anti-angiogenic Ophthalmic Agent Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Gilead Sciences, Inc. Basic Information, Manufacturing Base and Competitors
Table 62. Gilead Sciences, Inc. Major Business
Table 63. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
Table 64. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Gilead Sciences, Inc. Recent Developments/Updates
Table 66. Gilead Sciences, Inc. Competitive Strengths & Weaknesses
Table 67. Eyetech Inc. Basic Information, Manufacturing Base and Competitors
Table 68. Eyetech Inc. Major Business
Table 69. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product and Services
Table 70. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Eyetech Inc. Recent Developments/Updates
Table 72. Eyetech Inc. Competitive Strengths & Weaknesses
Table 73. Becton, Dickinson and Company Basic Information, Manufacturing Base and Competitors
Table 74. Becton, Dickinson and Company Major Business
Table 75. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product and Services
Table 76. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Becton, Dickinson and Company Recent Developments/Updates
Table 78. Becton, Dickinson and Company Competitive Strengths & Weaknesses
Table 79. Regeneron Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 80. Regeneron Pharmaceuticals, Inc. Major Business
Table 81. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
Table 82. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
Table 84. Regeneron Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
Table 85. Genentech, Inc. Basic Information, Manufacturing Base and Competitors
Table 86. Genentech, Inc. Major Business
Table 87. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
Table 88. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Genentech, Inc. Recent Developments/Updates
Table 90. Genentech, Inc. Competitive Strengths & Weaknesses
Table 91. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 92. Novartis AG Major Business
Table 93. Novartis AG Anti-angiogenic Ophthalmic Agent Product and Services
Table 94. Novartis AG Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Novartis AG Recent Developments/Updates
Table 96. Novartis AG Competitive Strengths & Weaknesses
Table 97. Allergan plc Basic Information, Manufacturing Base and Competitors
Table 98. Allergan plc Major Business
Table 99. Allergan plc Anti-angiogenic Ophthalmic Agent Product and Services
Table 100. Allergan plc Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Allergan plc Recent Developments/Updates
Table 102. Allergan plc Competitive Strengths & Weaknesses
Table 103. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 104. Bayer AG Major Business
Table 105. Bayer AG Anti-angiogenic Ophthalmic Agent Product and Services
Table 106. Bayer AG Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Bayer AG Recent Developments/Updates
Table 108. Bayer AG Competitive Strengths & Weaknesses
Table 109. Santen Pharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 110. Santen Pharmaceutical Co., Ltd. Major Business
Table 111. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product and Services
Table 112. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. Santen Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 114. Santen Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
Table 115. Shanghai Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 116. Shanghai Pharmaceuticals Major Business
Table 117. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product and Services
Table 118. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. Shanghai Pharmaceuticals Recent Developments/Updates
Table 120. Shanghai Pharmaceuticals Competitive Strengths & Weaknesses
Table 121. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 122. Johnson & Johnson Major Business
Table 123. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product and Services
Table 124. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 125. Johnson & Johnson Recent Developments/Updates
Table 126. Johnson & Johnson Competitive Strengths & Weaknesses
Table 127. Pfizer Basic Information, Manufacturing Base and Competitors
Table 128. Pfizer Major Business
Table 129. Pfizer Anti-angiogenic Ophthalmic Agent Product and Services
Table 130. Pfizer Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 131. Pfizer Recent Developments/Updates
Table 132. Pfizer Competitive Strengths & Weaknesses
Table 133. Sun Pharma Basic Information, Manufacturing Base and Competitors
Table 134. Sun Pharma Major Business
Table 135. Sun Pharma Anti-angiogenic Ophthalmic Agent Product and Services
Table 136. Sun Pharma Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 137. Sun Pharma Recent Developments/Updates
Table 138. Sun Pharma Competitive Strengths & Weaknesses
Table 139. Otsuka Pharmaceutical Co. Ltd Basic Information, Manufacturing Base and Competitors
Table 140. Otsuka Pharmaceutical Co. Ltd Major Business
Table 141. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product and Services
Table 142. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 143. Otsuka Pharmaceutical Co. Ltd Recent Developments/Updates
Table 144. Otsuka Pharmaceutical Co. Ltd Competitive Strengths & Weaknesses
Table 145. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 146. Daiichi Sankyo Major Business
Table 147. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product and Services
Table 148. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 149. Daiichi Sankyo Recent Developments/Updates
Table 150. Daiichi Sankyo Competitive Strengths & Weaknesses
Table 151. ERC Labs Basic Information, Manufacturing Base and Competitors
Table 152. ERC Labs Major Business
Table 153. ERC Labs Anti-angiogenic Ophthalmic Agent Product and Services
Table 154. ERC Labs Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 155. ERC Labs Recent Developments/Updates
Table 156. ERC Labs Competitive Strengths & Weaknesses
Table 157. Medicom Health care Basic Information, Manufacturing Base and Competitors
Table 158. Medicom Health care Major Business
Table 159. Medicom Health care Anti-angiogenic Ophthalmic Agent Product and Services
Table 160. Medicom Health care Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 161. Medicom Health care Recent Developments/Updates
Table 162. Medicom Health care Competitive Strengths & Weaknesses
Table 163. Implant ophthalmic products GmbH Basic Information, Manufacturing Base and Competitors
Table 164. Implant ophthalmic products GmbH Major Business
Table 165. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product and Services
Table 166. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 167. Implant ophthalmic products GmbH Recent Developments/Updates
Table 168. Implant ophthalmic products GmbH Competitive Strengths & Weaknesses
Table 169. The Geuder Group, MORCHER GmbH Basic Information, Manufacturing Base and Competitors
Table 170. The Geuder Group, MORCHER GmbH Major Business
Table 171. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product and Services
Table 172. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 173. The Geuder Group, MORCHER GmbH Recent Developments/Updates
Table 174. Novamedika Basic Information, Manufacturing Base and Competitors
Table 175. Novamedika Major Business
Table 176. Novamedika Anti-angiogenic Ophthalmic Agent Product and Services
Table 177. Novamedika Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 178. Global Key Players of Anti-angiogenic Ophthalmic Agent Upstream (Raw Materials)
Table 179. Anti-angiogenic Ophthalmic Agent Typical Customers
Table 180. Anti-angiogenic Ophthalmic Agent Typical Distributors
Table 1. World Anti-angiogenic Ophthalmic Agent Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Anti-angiogenic Ophthalmic Agent Production Value by Region (2018-2023) & (USD Million)
Table 3. World Anti-angiogenic Ophthalmic Agent Production Value by Region (2024-2029) & (USD Million)
Table 4. World Anti-angiogenic Ophthalmic Agent Production Value Market Share by Region (2018-2023)
Table 5. World Anti-angiogenic Ophthalmic Agent Production Value Market Share by Region (2024-2029)
Table 6. World Anti-angiogenic Ophthalmic Agent Production by Region (2018-2023) & (K Units)
Table 7. World Anti-angiogenic Ophthalmic Agent Production by Region (2024-2029) & (K Units)
Table 8. World Anti-angiogenic Ophthalmic Agent Production Market Share by Region (2018-2023)
Table 9. World Anti-angiogenic Ophthalmic Agent Production Market Share by Region (2024-2029)
Table 10. World Anti-angiogenic Ophthalmic Agent Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Anti-angiogenic Ophthalmic Agent Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Anti-angiogenic Ophthalmic Agent Major Market Trends
Table 13. World Anti-angiogenic Ophthalmic Agent Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Anti-angiogenic Ophthalmic Agent Consumption by Region (2018-2023) & (K Units)
Table 15. World Anti-angiogenic Ophthalmic Agent Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Anti-angiogenic Ophthalmic Agent Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Anti-angiogenic Ophthalmic Agent Producers in 2022
Table 18. World Anti-angiogenic Ophthalmic Agent Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Anti-angiogenic Ophthalmic Agent Producers in 2022
Table 20. World Anti-angiogenic Ophthalmic Agent Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Anti-angiogenic Ophthalmic Agent Company Evaluation Quadrant
Table 22. World Anti-angiogenic Ophthalmic Agent Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Anti-angiogenic Ophthalmic Agent Production Site of Key Manufacturer
Table 24. Anti-angiogenic Ophthalmic Agent Market: Company Product Type Footprint
Table 25. Anti-angiogenic Ophthalmic Agent Market: Company Product Application Footprint
Table 26. Anti-angiogenic Ophthalmic Agent Competitive Factors
Table 27. Anti-angiogenic Ophthalmic Agent New Entrant and Capacity Expansion Plans
Table 28. Anti-angiogenic Ophthalmic Agent Mergers & Acquisitions Activity
Table 29. United States VS China Anti-angiogenic Ophthalmic Agent Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Anti-angiogenic Ophthalmic Agent Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Anti-angiogenic Ophthalmic Agent Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Anti-angiogenic Ophthalmic Agent Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Anti-angiogenic Ophthalmic Agent Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Market Share (2018-2023)
Table 37. China Based Anti-angiogenic Ophthalmic Agent Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Anti-angiogenic Ophthalmic Agent Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Market Share (2018-2023)
Table 42. Rest of World Based Anti-angiogenic Ophthalmic Agent Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Anti-angiogenic Ophthalmic Agent Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Market Share (2018-2023)
Table 47. World Anti-angiogenic Ophthalmic Agent Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Anti-angiogenic Ophthalmic Agent Production by Type (2018-2023) & (K Units)
Table 49. World Anti-angiogenic Ophthalmic Agent Production by Type (2024-2029) & (K Units)
Table 50. World Anti-angiogenic Ophthalmic Agent Production Value by Type (2018-2023) & (USD Million)
Table 51. World Anti-angiogenic Ophthalmic Agent Production Value by Type (2024-2029) & (USD Million)
Table 52. World Anti-angiogenic Ophthalmic Agent Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Anti-angiogenic Ophthalmic Agent Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Anti-angiogenic Ophthalmic Agent Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Anti-angiogenic Ophthalmic Agent Production by Application (2018-2023) & (K Units)
Table 56. World Anti-angiogenic Ophthalmic Agent Production by Application (2024-2029) & (K Units)
Table 57. World Anti-angiogenic Ophthalmic Agent Production Value by Application (2018-2023) & (USD Million)
Table 58. World Anti-angiogenic Ophthalmic Agent Production Value by Application (2024-2029) & (USD Million)
Table 59. World Anti-angiogenic Ophthalmic Agent Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Anti-angiogenic Ophthalmic Agent Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Gilead Sciences, Inc. Basic Information, Manufacturing Base and Competitors
Table 62. Gilead Sciences, Inc. Major Business
Table 63. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
Table 64. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Gilead Sciences, Inc. Recent Developments/Updates
Table 66. Gilead Sciences, Inc. Competitive Strengths & Weaknesses
Table 67. Eyetech Inc. Basic Information, Manufacturing Base and Competitors
Table 68. Eyetech Inc. Major Business
Table 69. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product and Services
Table 70. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Eyetech Inc. Recent Developments/Updates
Table 72. Eyetech Inc. Competitive Strengths & Weaknesses
Table 73. Becton, Dickinson and Company Basic Information, Manufacturing Base and Competitors
Table 74. Becton, Dickinson and Company Major Business
Table 75. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product and Services
Table 76. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Becton, Dickinson and Company Recent Developments/Updates
Table 78. Becton, Dickinson and Company Competitive Strengths & Weaknesses
Table 79. Regeneron Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 80. Regeneron Pharmaceuticals, Inc. Major Business
Table 81. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
Table 82. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
Table 84. Regeneron Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
Table 85. Genentech, Inc. Basic Information, Manufacturing Base and Competitors
Table 86. Genentech, Inc. Major Business
Table 87. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product and Services
Table 88. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Genentech, Inc. Recent Developments/Updates
Table 90. Genentech, Inc. Competitive Strengths & Weaknesses
Table 91. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 92. Novartis AG Major Business
Table 93. Novartis AG Anti-angiogenic Ophthalmic Agent Product and Services
Table 94. Novartis AG Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Novartis AG Recent Developments/Updates
Table 96. Novartis AG Competitive Strengths & Weaknesses
Table 97. Allergan plc Basic Information, Manufacturing Base and Competitors
Table 98. Allergan plc Major Business
Table 99. Allergan plc Anti-angiogenic Ophthalmic Agent Product and Services
Table 100. Allergan plc Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Allergan plc Recent Developments/Updates
Table 102. Allergan plc Competitive Strengths & Weaknesses
Table 103. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 104. Bayer AG Major Business
Table 105. Bayer AG Anti-angiogenic Ophthalmic Agent Product and Services
Table 106. Bayer AG Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Bayer AG Recent Developments/Updates
Table 108. Bayer AG Competitive Strengths & Weaknesses
Table 109. Santen Pharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 110. Santen Pharmaceutical Co., Ltd. Major Business
Table 111. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product and Services
Table 112. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. Santen Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 114. Santen Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
Table 115. Shanghai Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 116. Shanghai Pharmaceuticals Major Business
Table 117. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product and Services
Table 118. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. Shanghai Pharmaceuticals Recent Developments/Updates
Table 120. Shanghai Pharmaceuticals Competitive Strengths & Weaknesses
Table 121. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 122. Johnson & Johnson Major Business
Table 123. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product and Services
Table 124. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 125. Johnson & Johnson Recent Developments/Updates
Table 126. Johnson & Johnson Competitive Strengths & Weaknesses
Table 127. Pfizer Basic Information, Manufacturing Base and Competitors
Table 128. Pfizer Major Business
Table 129. Pfizer Anti-angiogenic Ophthalmic Agent Product and Services
Table 130. Pfizer Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 131. Pfizer Recent Developments/Updates
Table 132. Pfizer Competitive Strengths & Weaknesses
Table 133. Sun Pharma Basic Information, Manufacturing Base and Competitors
Table 134. Sun Pharma Major Business
Table 135. Sun Pharma Anti-angiogenic Ophthalmic Agent Product and Services
Table 136. Sun Pharma Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 137. Sun Pharma Recent Developments/Updates
Table 138. Sun Pharma Competitive Strengths & Weaknesses
Table 139. Otsuka Pharmaceutical Co. Ltd Basic Information, Manufacturing Base and Competitors
Table 140. Otsuka Pharmaceutical Co. Ltd Major Business
Table 141. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product and Services
Table 142. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 143. Otsuka Pharmaceutical Co. Ltd Recent Developments/Updates
Table 144. Otsuka Pharmaceutical Co. Ltd Competitive Strengths & Weaknesses
Table 145. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 146. Daiichi Sankyo Major Business
Table 147. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product and Services
Table 148. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 149. Daiichi Sankyo Recent Developments/Updates
Table 150. Daiichi Sankyo Competitive Strengths & Weaknesses
Table 151. ERC Labs Basic Information, Manufacturing Base and Competitors
Table 152. ERC Labs Major Business
Table 153. ERC Labs Anti-angiogenic Ophthalmic Agent Product and Services
Table 154. ERC Labs Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 155. ERC Labs Recent Developments/Updates
Table 156. ERC Labs Competitive Strengths & Weaknesses
Table 157. Medicom Health care Basic Information, Manufacturing Base and Competitors
Table 158. Medicom Health care Major Business
Table 159. Medicom Health care Anti-angiogenic Ophthalmic Agent Product and Services
Table 160. Medicom Health care Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 161. Medicom Health care Recent Developments/Updates
Table 162. Medicom Health care Competitive Strengths & Weaknesses
Table 163. Implant ophthalmic products GmbH Basic Information, Manufacturing Base and Competitors
Table 164. Implant ophthalmic products GmbH Major Business
Table 165. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product and Services
Table 166. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 167. Implant ophthalmic products GmbH Recent Developments/Updates
Table 168. Implant ophthalmic products GmbH Competitive Strengths & Weaknesses
Table 169. The Geuder Group, MORCHER GmbH Basic Information, Manufacturing Base and Competitors
Table 170. The Geuder Group, MORCHER GmbH Major Business
Table 171. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product and Services
Table 172. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 173. The Geuder Group, MORCHER GmbH Recent Developments/Updates
Table 174. Novamedika Basic Information, Manufacturing Base and Competitors
Table 175. Novamedika Major Business
Table 176. Novamedika Anti-angiogenic Ophthalmic Agent Product and Services
Table 177. Novamedika Anti-angiogenic Ophthalmic Agent Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 178. Global Key Players of Anti-angiogenic Ophthalmic Agent Upstream (Raw Materials)
Table 179. Anti-angiogenic Ophthalmic Agent Typical Customers
Table 180. Anti-angiogenic Ophthalmic Agent Typical Distributors
LIST OF FIGURES
Figure 1. Anti-angiogenic Ophthalmic Agent Picture
Figure 2. World Anti-angiogenic Ophthalmic Agent Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Anti-angiogenic Ophthalmic Agent Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Anti-angiogenic Ophthalmic Agent Production (2018-2029) & (K Units)
Figure 5. World Anti-angiogenic Ophthalmic Agent Average Price (2018-2029) & (US$/Unit)
Figure 6. World Anti-angiogenic Ophthalmic Agent Production Value Market Share by Region (2018-2029)
Figure 7. World Anti-angiogenic Ophthalmic Agent Production Market Share by Region (2018-2029)
Figure 8. North America Anti-angiogenic Ophthalmic Agent Production (2018-2029) & (K Units)
Figure 9. Europe Anti-angiogenic Ophthalmic Agent Production (2018-2029) & (K Units)
Figure 10. China Anti-angiogenic Ophthalmic Agent Production (2018-2029) & (K Units)
Figure 11. Japan Anti-angiogenic Ophthalmic Agent Production (2018-2029) & (K Units)
Figure 12. Anti-angiogenic Ophthalmic Agent Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Anti-angiogenic Ophthalmic Agent Consumption (2018-2029) & (K Units)
Figure 15. World Anti-angiogenic Ophthalmic Agent Consumption Market Share by Region (2018-2029)
Figure 16. United States Anti-angiogenic Ophthalmic Agent Consumption (2018-2029) & (K Units)
Figure 17. China Anti-angiogenic Ophthalmic Agent Consumption (2018-2029) & (K Units)
Figure 18. Europe Anti-angiogenic Ophthalmic Agent Consumption (2018-2029) & (K Units)
Figure 19. Japan Anti-angiogenic Ophthalmic Agent Consumption (2018-2029) & (K Units)
Figure 20. South Korea Anti-angiogenic Ophthalmic Agent Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Anti-angiogenic Ophthalmic Agent Consumption (2018-2029) & (K Units)
Figure 22. India Anti-angiogenic Ophthalmic Agent Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Anti-angiogenic Ophthalmic Agent by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Anti-angiogenic Ophthalmic Agent Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Anti-angiogenic Ophthalmic Agent Markets in 2022
Figure 26. United States VS China: Anti-angiogenic Ophthalmic Agent Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Anti-angiogenic Ophthalmic Agent Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Anti-angiogenic Ophthalmic Agent Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Market Share 2022
Figure 30. China Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Market Share 2022
Figure 32. World Anti-angiogenic Ophthalmic Agent Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Anti-angiogenic Ophthalmic Agent Production Value Market Share by Type in 2022
Figure 34. Myopic Choroidal Neovascularization
Figure 35. Macular Edema
Figure 36. Diabetic Retinopathy
Figure 37. Macular Degeneration
Figure 38. World Anti-angiogenic Ophthalmic Agent Production Market Share by Type (2018-2029)
Figure 39. World Anti-angiogenic Ophthalmic Agent Production Value Market Share by Type (2018-2029)
Figure 40. World Anti-angiogenic Ophthalmic Agent Average Price by Type (2018-2029) & (US$/Unit)
Figure 41. World Anti-angiogenic Ophthalmic Agent Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 42. World Anti-angiogenic Ophthalmic Agent Production Value Market Share by Application in 2022
Figure 43. Retail Pharmacies
Figure 44. Online Pharmacies
Figure 45. Hospital Pharmacies
Figure 46. World Anti-angiogenic Ophthalmic Agent Production Market Share by Application (2018-2029)
Figure 47. World Anti-angiogenic Ophthalmic Agent Production Value Market Share by Application (2018-2029)
Figure 48. World Anti-angiogenic Ophthalmic Agent Average Price by Application (2018-2029) & (US$/Unit)
Figure 49. Anti-angiogenic Ophthalmic Agent Industry Chain
Figure 50. Anti-angiogenic Ophthalmic Agent Procurement Model
Figure 51. Anti-angiogenic Ophthalmic Agent Sales Model
Figure 52. Anti-angiogenic Ophthalmic Agent Sales Channels, Direct Sales, and Distribution
Figure 53. Methodology
Figure 54. Research Process and Data Source
Figure 1. Anti-angiogenic Ophthalmic Agent Picture
Figure 2. World Anti-angiogenic Ophthalmic Agent Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Anti-angiogenic Ophthalmic Agent Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Anti-angiogenic Ophthalmic Agent Production (2018-2029) & (K Units)
Figure 5. World Anti-angiogenic Ophthalmic Agent Average Price (2018-2029) & (US$/Unit)
Figure 6. World Anti-angiogenic Ophthalmic Agent Production Value Market Share by Region (2018-2029)
Figure 7. World Anti-angiogenic Ophthalmic Agent Production Market Share by Region (2018-2029)
Figure 8. North America Anti-angiogenic Ophthalmic Agent Production (2018-2029) & (K Units)
Figure 9. Europe Anti-angiogenic Ophthalmic Agent Production (2018-2029) & (K Units)
Figure 10. China Anti-angiogenic Ophthalmic Agent Production (2018-2029) & (K Units)
Figure 11. Japan Anti-angiogenic Ophthalmic Agent Production (2018-2029) & (K Units)
Figure 12. Anti-angiogenic Ophthalmic Agent Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Anti-angiogenic Ophthalmic Agent Consumption (2018-2029) & (K Units)
Figure 15. World Anti-angiogenic Ophthalmic Agent Consumption Market Share by Region (2018-2029)
Figure 16. United States Anti-angiogenic Ophthalmic Agent Consumption (2018-2029) & (K Units)
Figure 17. China Anti-angiogenic Ophthalmic Agent Consumption (2018-2029) & (K Units)
Figure 18. Europe Anti-angiogenic Ophthalmic Agent Consumption (2018-2029) & (K Units)
Figure 19. Japan Anti-angiogenic Ophthalmic Agent Consumption (2018-2029) & (K Units)
Figure 20. South Korea Anti-angiogenic Ophthalmic Agent Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Anti-angiogenic Ophthalmic Agent Consumption (2018-2029) & (K Units)
Figure 22. India Anti-angiogenic Ophthalmic Agent Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Anti-angiogenic Ophthalmic Agent by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Anti-angiogenic Ophthalmic Agent Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Anti-angiogenic Ophthalmic Agent Markets in 2022
Figure 26. United States VS China: Anti-angiogenic Ophthalmic Agent Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Anti-angiogenic Ophthalmic Agent Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Anti-angiogenic Ophthalmic Agent Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Market Share 2022
Figure 30. China Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Anti-angiogenic Ophthalmic Agent Production Market Share 2022
Figure 32. World Anti-angiogenic Ophthalmic Agent Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Anti-angiogenic Ophthalmic Agent Production Value Market Share by Type in 2022
Figure 34. Myopic Choroidal Neovascularization
Figure 35. Macular Edema
Figure 36. Diabetic Retinopathy
Figure 37. Macular Degeneration
Figure 38. World Anti-angiogenic Ophthalmic Agent Production Market Share by Type (2018-2029)
Figure 39. World Anti-angiogenic Ophthalmic Agent Production Value Market Share by Type (2018-2029)
Figure 40. World Anti-angiogenic Ophthalmic Agent Average Price by Type (2018-2029) & (US$/Unit)
Figure 41. World Anti-angiogenic Ophthalmic Agent Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 42. World Anti-angiogenic Ophthalmic Agent Production Value Market Share by Application in 2022
Figure 43. Retail Pharmacies
Figure 44. Online Pharmacies
Figure 45. Hospital Pharmacies
Figure 46. World Anti-angiogenic Ophthalmic Agent Production Market Share by Application (2018-2029)
Figure 47. World Anti-angiogenic Ophthalmic Agent Production Value Market Share by Application (2018-2029)
Figure 48. World Anti-angiogenic Ophthalmic Agent Average Price by Application (2018-2029) & (US$/Unit)
Figure 49. Anti-angiogenic Ophthalmic Agent Industry Chain
Figure 50. Anti-angiogenic Ophthalmic Agent Procurement Model
Figure 51. Anti-angiogenic Ophthalmic Agent Sales Model
Figure 52. Anti-angiogenic Ophthalmic Agent Sales Channels, Direct Sales, and Distribution
Figure 53. Methodology
Figure 54. Research Process and Data Source
